COVID (Feb 2024)

Development of Mouse Hepatitis Virus Chimeric Reporter Viruses Expressing the 3CLpro Proteases of Human Coronaviruses HKU1 and OC43 Reveals Susceptibility to Inactivation by Natural Inhibitors Baicalin and Baicalein

  • Elise R. Huffman,
  • Jared X. Franges,
  • Jayden M. Doster,
  • Alexis R. Armstrong,
  • Yara S. Batista,
  • Cameron M. Harrison,
  • Jon D. Brooks,
  • Morgan N. Thomas,
  • Butler Student Virology Group,
  • Sakshi Tomar,
  • Christopher C. Stobart,
  • Dia C. Beachboard

DOI
https://doi.org/10.3390/covid4020016
Journal volume & issue
Vol. 4, no. 2
pp. 208 – 220

Abstract

Read online

The recent emergence of SARS-CoV-2 in 2019 has highlighted the necessity of antiviral therapeutics for current and future emerging coronaviruses. Recently, the traditional herbal medicines baicalein, baicalin, and andrographolide have shown inhibition against the main protease of SARS-CoV-2. This provides a promising new direction for COVID-19 therapeutics, but it remains unknown whether these three substances inhibit other human coronaviruses. In this study, we describe the development of novel chimeric mouse hepatitis virus (MHV) reporters that express firefly luciferase (FFL) and the 3CLpro proteases of human coronaviruses HKU1 and OC43. These chimeric viruses were used to determine if the phytochemicals baicalein, baicalin, and andrographolide are inhibitory against human coronavirus strains HKU1 and OC43. Our data show that both baicalein and baicalin exhibit inhibition towards the chimeric MHV strains. However, andrographolide induces cytotoxicity and failed to demonstrate selective toxicity towards the viruses. This study reports the development and use of a safe replicating reporter platform to investigate potential coronavirus 3CLpro inhibitors against common-cold human coronavirus strains HKU1 and OC43.

Keywords